WO2012136534A3 - Verwendung eines mittels aus antikörpern und/oder insulin-like growth factor-antagonisten - Google Patents

Verwendung eines mittels aus antikörpern und/oder insulin-like growth factor-antagonisten Download PDF

Info

Publication number
WO2012136534A3
WO2012136534A3 PCT/EP2012/055485 EP2012055485W WO2012136534A3 WO 2012136534 A3 WO2012136534 A3 WO 2012136534A3 EP 2012055485 W EP2012055485 W EP 2012055485W WO 2012136534 A3 WO2012136534 A3 WO 2012136534A3
Authority
WO
WIPO (PCT)
Prior art keywords
insulin
antibodies
growth factor
agent consisting
factor antagonists
Prior art date
Application number
PCT/EP2012/055485
Other languages
English (en)
French (fr)
Other versions
WO2012136534A2 (de
Inventor
Jan WESJOHANN
Günter SPROTTE
Ana Maria WAAGA-GASSER
Original Assignee
Mat-Malta Advanced Technologies Limited
Freistaat Bayern vertreten durch die Julius-Maximilians-Universität Würzburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mat-Malta Advanced Technologies Limited, Freistaat Bayern vertreten durch die Julius-Maximilians-Universität Würzburg filed Critical Mat-Malta Advanced Technologies Limited
Priority to KR1020137029359A priority Critical patent/KR20140031892A/ko
Priority to MX2013011629A priority patent/MX2013011629A/es
Priority to CA2832373A priority patent/CA2832373A1/en
Priority to BR112013025906A priority patent/BR112013025906A2/pt
Priority to AU2012238872A priority patent/AU2012238872A1/en
Priority to EP12710749.8A priority patent/EP2694540A2/de
Priority to US14/110,104 priority patent/US9801938B2/en
Publication of WO2012136534A2 publication Critical patent/WO2012136534A2/de
Publication of WO2012136534A3 publication Critical patent/WO2012136534A3/de
Priority to ZA2013/07986A priority patent/ZA201307986B/en
Priority to US15/433,497 priority patent/US9913904B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1235—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Salmonella (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1275—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Die vorliegende Erfindung betrifft die Verwendung eines Mittels, ausgewählt aus der Gruppe bestehend aus Antikörpern, Antikörper-Teilen, Insulin-like growth factor-Antagonisten, Toll-like-Rezeptor-Antagonisten und deren Mischungen zur Behandlung oder zur Prophylaxe bestimmter Krankheiten.
PCT/EP2012/055485 2011-04-05 2012-03-28 Verwendung eines mittels aus antikörpern und/oder insulin-like growth factor-antagonisten WO2012136534A2 (de)

Priority Applications (9)

Application Number Priority Date Filing Date Title
KR1020137029359A KR20140031892A (ko) 2011-04-05 2012-03-28 항체 및/또는 인슐린 유사 성장 인자 길항제로 이루어진 약물의 용도
MX2013011629A MX2013011629A (es) 2011-04-05 2012-03-28 Uso de un agente que consiste en anticuerpos y/o antagonistas de factor de crecimiento tipo insulina.
CA2832373A CA2832373A1 (en) 2011-04-05 2012-03-28 Use of an agent consisting of antibodies and/or insulin-like growth factor antagonists
BR112013025906A BR112013025906A2 (pt) 2011-04-05 2012-03-28 "preparação farmacêutica compreendendo anticorpos imunoglobulina y ou seus fragmentos, e seu uso".
AU2012238872A AU2012238872A1 (en) 2011-04-05 2012-03-28 Use of an agent consisting of antibodies and/or insulin-like growth factor antagonists
EP12710749.8A EP2694540A2 (de) 2011-04-05 2012-03-28 Verwendung eines mittels aus antikörpern und/oder insulin-like growth factor-antagonisten
US14/110,104 US9801938B2 (en) 2011-04-05 2012-03-28 Use of an agent consisting of antibodies and/or insulin-like growth factor antagonists
ZA2013/07986A ZA201307986B (en) 2011-04-05 2013-10-24 Use of an agent consisting of antibodies and/or insulin-like growth factor antagonists
US15/433,497 US9913904B2 (en) 2011-04-05 2017-02-15 Use of an agent consisting of antibodies and/or insulin-like growth factor antagonists

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102011006809A DE102011006809A1 (de) 2011-04-05 2011-04-05 Verwendung eines Mittels aus Antikörpern und/oder Insulin-like growth factor-Antagonisten
DE102011006809.0 2011-04-05

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US14/110,104 A-371-Of-International US9801938B2 (en) 2011-04-05 2012-03-28 Use of an agent consisting of antibodies and/or insulin-like growth factor antagonists
US15/433,497 Division US9913904B2 (en) 2011-04-05 2017-02-15 Use of an agent consisting of antibodies and/or insulin-like growth factor antagonists

Publications (2)

Publication Number Publication Date
WO2012136534A2 WO2012136534A2 (de) 2012-10-11
WO2012136534A3 true WO2012136534A3 (de) 2012-11-29

Family

ID=45888234

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2012/055485 WO2012136534A2 (de) 2011-04-05 2012-03-28 Verwendung eines mittels aus antikörpern und/oder insulin-like growth factor-antagonisten

Country Status (10)

Country Link
US (2) US9801938B2 (de)
EP (1) EP2694540A2 (de)
KR (1) KR20140031892A (de)
AU (1) AU2012238872A1 (de)
BR (1) BR112013025906A2 (de)
CA (1) CA2832373A1 (de)
DE (1) DE102011006809A1 (de)
MX (1) MX2013011629A (de)
WO (1) WO2012136534A2 (de)
ZA (1) ZA201307986B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102011006809A1 (de) 2011-04-05 2012-10-11 Freistaat Bayern vertreten durch die Julius-Maximilians-Universität Würzburg Verwendung eines Mittels aus Antikörpern und/oder Insulin-like growth factor-Antagonisten
DE102011006781A1 (de) * 2011-04-05 2012-10-11 Mat-Malta Advanced Technologies Limited Antikörperprodukt, umfassend n spezifische Antikörper
JP2018512857A (ja) * 2015-04-17 2018-05-24 ユリウス・マクシミリアンス−ウニヴェルジテート・ヴュルツブルクＪｕｌｉｕｓ Ｍａｘｉｍｉｌｉａｎｓ−Ｕｎｉｖｅｒｓｉｔａｅｔ Ｗｕｅｒｚｂｕｒｇ 抗ｌｐｓ免疫グロブリン処置に対する臨床応答の予測バイオマーカー
WO2020147950A1 (en) 2019-01-16 2020-07-23 Ignova Gmbh Methods of treating fibromyalgia
US11319382B1 (en) 2021-06-28 2022-05-03 King Abdulaziz University Methods for producing and using IgY antibodies targeting the middle east respiratory syndrome coronavirus spike protein to treat or prevent MERS-CoV infection
CN117860727A (zh) * 2022-09-26 2024-04-12 江苏海洋大学 一种用于预防或治疗疼痛的药物组合物

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0781560A1 (de) * 1995-12-22 1997-07-02 Biotest Pharma Gmbh Verwendung von Immunglobulin-Präparationen zur Herstellung eines Medikaments zur oralen Verabreichung zur Behandlung und Prophylaxe chronischer Schmerzzustände
EP1125585A1 (de) * 1999-08-30 2001-08-22 Japan Tobacco Inc. Behandlung von erkrankungen des immunsystems
WO2002002641A1 (en) * 2000-06-16 2002-01-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to blys
US20030099633A1 (en) * 2001-10-09 2003-05-29 Campbell Joy M. Methods and compositions for treatment of immune dysfunction disorders
US20060034846A1 (en) * 2003-04-14 2006-02-16 Mirella Ezban Use of TF antagonists
US20070122413A1 (en) * 2005-11-28 2007-05-31 Sivakumar Pallavur V Il-21 antagonists
WO2008025099A1 (en) * 2006-08-31 2008-03-06 A.C.N. 135 493 391 Pty Ltd As Trustee For Conca Unit Trust Treatment and/or prevention of non-infectious medical conditions using antibody-containing compositions
WO2008067234A2 (en) * 2006-11-28 2008-06-05 Warsaw Orthopedic, Inc Use of anti-cytokine agents for treating carpal and tarsal tunnel syndrome
WO2008073463A2 (en) * 2006-12-11 2008-06-19 Wyeth Methods and compositions for treating and monitoring treatment of il-13-associated disorders
EP1982999A1 (de) * 2007-04-16 2008-10-22 Friesland Brands B.V. Antigenspezifische Antikörper aus der Milch, Herstellungsverfahren und Verwendung
WO2009077993A2 (en) * 2007-12-17 2009-06-25 Pfizer Limited Treatment of interstitial cystitis
WO2009113065A1 (en) * 2008-03-13 2009-09-17 Hadasit Medical Research Services & Development Ltd. Immuno-modulating compositions for the treatment of immune-mediated disorders
WO2009151717A2 (en) * 2008-04-02 2009-12-17 Macrogenics, Inc. Bcr-complex-specific antibodies and methods of using same
WO2010125565A2 (en) * 2009-04-27 2010-11-04 Hadasit Medical Research Services And Development Ltd. Anti-lps enriched immunoglobulin preparation for use in treatment and/or prophylaxis of a pathologic disorder

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2052496T3 (es) * 1985-11-25 1994-07-16 Ghen Corp Sustancia que contiene anticuerpo especifico obtenida de huevos y metodo para su produccion y uso.
EP0338229B1 (de) * 1988-04-19 1993-06-16 Biotest Pharma Gmbh Präparat mit Antikörperaktivität und breitem Wirkungsspektrum, daraus bestehende oder diese enthaltende Mittel und deren Verwendung zur Behandlung von bakteriell oder toxin-bedingten Erkrankungen und zur Bekämpfung von Protozoen
US5332567A (en) 1989-08-24 1994-07-26 Immunomedics Detection and treatment of infections with immunoconjugates
JP3195631B2 (ja) * 1991-02-16 2001-08-06 太陽化学株式会社 特異的鶏卵抗体の製造方法
GB9105292D0 (en) 1991-03-13 1991-04-24 Sandoz Ltd Improvements in or relating to organic compounds
AUPN115095A0 (en) * 1995-02-15 1995-03-09 Butt, Henry Lawrence Analysis of and compositions and methods for the treatment of disease
CZ287989B6 (cs) 1998-03-20 2001-03-14 Medipharm Cz, S. R. O. Perorální přípravek k prevenci a léčbě infekčních gastroenteritid prasat
US6346247B1 (en) 1999-10-28 2002-02-12 Promega Corporation Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies
US7355092B2 (en) 1999-12-27 2008-04-08 Ronald Marquardt Genetic vaccines for the production of chicken egg-yolk antibodies against enterotoxigenic Escherichia coli and other pathogens
AU2003901008A0 (en) 2003-03-04 2003-03-20 Anadis Ltd Composition for the treatment and prevention of bacterial infections
KR101233648B1 (ko) 2004-09-29 2013-02-15 시즈오카켄 유청 단백, 젖 유래의 항체 또는 항체를 포함하는 기능성조성물 또는 식품
WO2009092383A2 (en) 2008-01-22 2009-07-30 Multimerics Aps Products and methods to prevent infection
EP2480255B1 (de) 2009-09-23 2017-11-22 Thomas Julius Borody Therapie für kronische darminfektionen
DK2605791T3 (en) 2010-08-17 2017-06-19 Immuron Ltd ANTI-LPS ENHANCED IMMUNOGLOBULIN PREPARATION FOR USE IN TREATMENT AND / OR PROPHYLAXY OF A PATHOLOGICAL DISORDER
EP2624844A4 (de) 2010-10-04 2014-03-26 Immuron Ltd Verfahren und zusammensetzungen mit anti-lps-liganden zur behandlung und vorbeugung von entzündungserkrankungen
DE102011006809A1 (de) 2011-04-05 2012-10-11 Freistaat Bayern vertreten durch die Julius-Maximilians-Universität Würzburg Verwendung eines Mittels aus Antikörpern und/oder Insulin-like growth factor-Antagonisten
DE102011006781A1 (de) 2011-04-05 2012-10-11 Mat-Malta Advanced Technologies Limited Antikörperprodukt, umfassend n spezifische Antikörper
WO2013009843A1 (en) 2011-07-11 2013-01-17 Camas Incorporated Compositions against bacterial toxins

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0781560A1 (de) * 1995-12-22 1997-07-02 Biotest Pharma Gmbh Verwendung von Immunglobulin-Präparationen zur Herstellung eines Medikaments zur oralen Verabreichung zur Behandlung und Prophylaxe chronischer Schmerzzustände
EP1125585A1 (de) * 1999-08-30 2001-08-22 Japan Tobacco Inc. Behandlung von erkrankungen des immunsystems
WO2002002641A1 (en) * 2000-06-16 2002-01-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to blys
US20030099633A1 (en) * 2001-10-09 2003-05-29 Campbell Joy M. Methods and compositions for treatment of immune dysfunction disorders
US20060034846A1 (en) * 2003-04-14 2006-02-16 Mirella Ezban Use of TF antagonists
US20070122413A1 (en) * 2005-11-28 2007-05-31 Sivakumar Pallavur V Il-21 antagonists
WO2008025099A1 (en) * 2006-08-31 2008-03-06 A.C.N. 135 493 391 Pty Ltd As Trustee For Conca Unit Trust Treatment and/or prevention of non-infectious medical conditions using antibody-containing compositions
WO2008067234A2 (en) * 2006-11-28 2008-06-05 Warsaw Orthopedic, Inc Use of anti-cytokine agents for treating carpal and tarsal tunnel syndrome
WO2008073463A2 (en) * 2006-12-11 2008-06-19 Wyeth Methods and compositions for treating and monitoring treatment of il-13-associated disorders
EP1982999A1 (de) * 2007-04-16 2008-10-22 Friesland Brands B.V. Antigenspezifische Antikörper aus der Milch, Herstellungsverfahren und Verwendung
WO2009077993A2 (en) * 2007-12-17 2009-06-25 Pfizer Limited Treatment of interstitial cystitis
WO2009113065A1 (en) * 2008-03-13 2009-09-17 Hadasit Medical Research Services & Development Ltd. Immuno-modulating compositions for the treatment of immune-mediated disorders
WO2009151717A2 (en) * 2008-04-02 2009-12-17 Macrogenics, Inc. Bcr-complex-specific antibodies and methods of using same
WO2010125565A2 (en) * 2009-04-27 2010-11-04 Hadasit Medical Research Services And Development Ltd. Anti-lps enriched immunoglobulin preparation for use in treatment and/or prophylaxis of a pathologic disorder

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CATS E A ET AL: "New liquid intravenous immunoglobulin (10 % IVIg) for treatment of multifocal motor neuropathy; A prospective study of efficacy, safety and tolerability", JOURNAL OF NEUROLOGY, STEINKOPFF-VERLAG, DA, vol. 255, no. 10, 3 September 2008 (2008-09-03), pages 1598 - 1599, XP019657652, ISSN: 1432-1459, DOI: 10.1007/S00415-008-0979-3 *
KAWAGASHIRA Y ET AL: "Differential response to intravenous immunoglobulin (IVIg) therapy among multifocal and polyneuropathy types of painful diabetic neuropathy", JOURNAL OF CLINICAL NEUROSCIENCE, CHURCHILL LIVINGSTONE, GB, vol. 17, no. 8, 1 August 2010 (2010-08-01), pages 1003 - 1008, XP027129028, ISSN: 0967-5868, [retrieved on 20100629] *
SCHADE R ET AL: "CHICKEN EGG YOLK ANTIBODIES (IGY-TECHNOLOGY): A REVIEW OF PROGRESS IN PRODUCTION AND USE IN RESEARCH AND HUMAN AND VETERINARY MEDICINE", ATLA. ALTERNATIVES TO LABORATORY ANIMALS, LONDON, GB, vol. 33, no. 2, 1 April 2005 (2005-04-01), pages 129 - 154, XP009057556, ISSN: 0261-1929 *
STRUFF W G ET AL: "Bovine colostrum as a biologic in clinical medicine: a review--Part II: clinical studies", INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, DUSTRI-VERLAG, DEISENHOFEN-MUENCHEN, DE, vol. 46, no. 5, 1 May 2008 (2008-05-01), pages 211 - 225, XP009150270, ISSN: 0946-1965 *
WAAGA-GASSER A M ET AL: "Oral immunoglobulin induces mononuclear cell apoptosis in patients suffering from idiopathic chronic pain syndrome: Results from a pilot study", INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, DUSTRI-VERLAG, DEISENHOFEN-MUENCHEN, DE, vol. 47, no. 7, 1 July 2009 (2009-07-01), pages 421 - 433, XP009150941, ISSN: 0946-1965 *

Also Published As

Publication number Publication date
AU2012238872A1 (en) 2013-10-31
KR20140031892A (ko) 2014-03-13
US9913904B2 (en) 2018-03-13
WO2012136534A2 (de) 2012-10-11
EP2694540A2 (de) 2014-02-12
US20140112937A1 (en) 2014-04-24
DE102011006809A1 (de) 2012-10-11
US9801938B2 (en) 2017-10-31
ZA201307986B (en) 2015-09-30
MX2013011629A (es) 2014-03-27
BR112013025906A2 (pt) 2016-09-06
US20170252438A1 (en) 2017-09-07
CA2832373A1 (en) 2012-10-11

Similar Documents

Publication Publication Date Title
HUS2000032I1 (hu) Helyettesített 4-fenil-piridinek NK-1 receptorral kapcsolatos betegségek kezelésére
WO2013119716A8 (en) Compositions and methods for using csf1r inhibitors
WO2012149356A3 (en) Anti-cd40 antibodies and methods of use
MX356337B (es) Anticuerpos contra csf-1r humano y sus usos.
PH12017500864A1 (en) Anti-notch1 antibodies
MX336682B (es) Anticuerpos contra csf-1r humanos y usos de los mismos.
TN2013000378A1 (en) Anti - sclerostin antibody crystals and formulations thereof
WO2014078268A8 (en) Anti-hemagglutinin antibodies and methods of use
WO2012118813A3 (en) Anti-il-6 receptor antibodies and methods of use
MA34091B1 (fr) Anticorps anti-cd40
WO2012064836A9 (en) Methods and compositions for neural disease immunotherapy
WO2012107416A3 (en) Improved immunotherapy
SG178886A1 (en) Humanized anti-cdcp1 antibodies
WO2012173846A3 (en) Peptidomimetic macrocycles
MX354988B (es) Formulaciones de anticuerpo y metodos.
WO2013188448A3 (en) Dual receptor antagonistic antigen-binding proteins and uses thereof
WO2012166626A8 (en) Reagents and methods for treating dental disease
WO2012136534A3 (de) Verwendung eines mittels aus antikörpern und/oder insulin-like growth factor-antagonisten
MX2014004074A (es) Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2.
EA201101241A1 (ru) Лечение лейкозов и хронических миелопролиферативных болезней антителами к ерна3
WO2015009740A3 (en) Anti-mucin 1 binding agents and uses thereof
WO2012149334A3 (en) Methods and compositions for the generation and use of conformation-specific antibodies
EA201391199A1 (ru) Композиции из hyr1-производных и способы лечения ими
WO2012080641A8 (fr) Agonistes des recepteurs s1p et leur utilisation dans le traitement des infections du vih
WO2013067160A3 (en) Anti-bacterial polypeptides and pathogen specific synthetic antibodies

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12710749

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
REEP Request for entry into the european phase

Ref document number: 2012710749

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2012710749

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2832373

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2013/011629

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2012238872

Country of ref document: AU

Date of ref document: 20120328

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20137029359

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 14110104

Country of ref document: US

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112013025906

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112013025906

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20131007